| ￥3500 | |
| Z04732-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 28.46 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 35-40 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of ANGPTL4/Angiopoietin-like 4, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »
ANGPTL4/Angiopoietin-like 4, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Candidates for this common regulatory system include signals mediated by peroxisome proliferator-activated regulator and its response factor, angiopoietin-like 4. The expression and bioactivity of angiopoietin-like 4, an adipocytokine that was originally reported to have an angiogenic function, have been detected not only in the vascular system and adipose tissue but also in rheumatoid joints. |
| Synonyms | ANGPTL4; ARP4; FIAF; HFARP; Angiopoietin like 4; NGPTL2; NL2; PGAR; pp1158; ANG-3; ANG4; AGP4; ANG3; ANG-3; ANG-4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
